US 12,465,633 B2
Lipopeptide building blocks and synthetic virus-like particles
Arin Ghasparian, Zürich (CH); and John A Robinson, Kemptthal (CH)
Assigned to VIROMETIX AG, Schlieren (CH); and UNIVERSITÄT ZÜRICH, Zürich (CH)
Appl. No. 17/415,305
Filed by VIROMETIX AG, Schlieren (CH); and UNIVERSITÄT ZÜRICH, Zürich (CH)
PCT Filed Dec. 19, 2019, PCT No. PCT/EP2019/086302
§ 371(c)(1), (2) Date Jun. 17, 2021,
PCT Pub. No. WO2020/127728, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 18214485 (EP), filed on Dec. 20, 2018.
Prior Publication US 2022/0054619 A1, Feb. 24, 2022
Int. Cl. C12N 7/00 (2006.01); A61K 39/12 (2006.01); A61P 31/14 (2006.01); C07K 14/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 31/14 (2018.01); C07K 14/001 (2013.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); A61K 2039/6018 (2013.01); C12N 2760/18523 (2013.01); C12N 2760/18534 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A lipopeptide building block consisting of:
(i) a peptide moiety comprising a coiled coil peptide chain segment, wherein said coiled coil peptide chain segment comprises 3 to 8 repeat units, wherein said repeat unit consists of the sequence IEKKIES (SEQ ID NO:13); and
(ii) a lipid moiety comprising the formula LM-I

OG Complex Work Unit Chemistry
wherein R1 and R2 are independently C11-15 alkyl, wherein R3 is hydrogen or —C(O) C11-15 alkyl;
wherein said lipid moiety is linked to said peptide moiety, and wherein the wavy line in formula LM-I indicates the linkage site to said peptide moiety.